@jonny@albertcardona@brembs Indeed the basic “all ‘legacy’ journals must die” premise is assumed correct in the question and includes NPG, but I am trying to be realistic about how much I can get in this battle — the authors list is overwhelmingly traditionalist and wary even of preprints. 😞 I'll push for eLife but even that is a stretch. Is it worth steering from Cell to Nature & co? I think so, but I'm worried it's just exposure bias. Profit margins at least seem lower at NPG. (26 vs 38%)